Search Results - "CARRERO, X"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Phase II trial of pirfenidone in adults with neurofibromatosis type 1

    Phase II trial of pirfenidone in adults with neurofibromatosis type 1 by BABOVIC-VUKSANOVIC, D, BALLMAN, K, SPINNER, R, O'NEILL, B, MICHELS, V, MCGRANN, P, LINDOR, N, KING, B, CAMP, J, MICIC, V, BABOVIC, N, CARRERO, X

    Published in Neurology (28-11-2006)
    “…We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC)

    Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) by Chan, E, Shi, Q, Garcia-Aguilar, J, Wolff, B.G, Johnson, C.S, Sanders, B, Carrero, X, Posner, M.C, Ota, D.M, Thomas, C.R

    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR)

    Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR) by Anderson, S. K., Lafky, J. M., Carrero, X. W., Kimlinger, T. K., Halling, T. M., Kumar, S., Flynn, P. J., Gross, H. M., Jaeckle, K. A., Buckner, J. C., Galanis, E.

    Published in Journal of clinical oncology (20-05-2011)
    “…Abstract only…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: